Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) Invested Capital: 2011-2025

Historic Invested Capital for Niagen Bioscience (NAGE) over the last 12 years, with Sep 2025 value amounting to $70.7 million.

  • Niagen Bioscience's Invested Capital rose 105.64% to $70.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.7 million, marking a year-over-year increase of 105.64%. This contributed to the annual value of $46.1 million for FY2024, which is 61.98% up from last year.
  • According to the latest figures from Q3 2025, Niagen Bioscience's Invested Capital is $70.7 million, which was up 10.10% from $64.2 million recorded in Q2 2025.
  • Niagen Bioscience's Invested Capital's 5-year high stood at $70.7 million during Q3 2025, with a 5-year trough of $20.8 million in Q2 2022.
  • Over the past 3 years, Niagen Bioscience's median Invested Capital value was $30.7 million (recorded in 2024), while the average stood at $40.1 million.
  • Its Invested Capital has fluctuated over the past 5 years, first slumped by 50.70% in 2022, then soared by 108.98% in 2025.
  • Quarterly analysis of 5 years shows Niagen Bioscience's Invested Capital stood at $31.7 million in 2021, then decreased by 9.63% to $28.7 million in 2022, then decreased by 0.75% to $28.5 million in 2023, then soared by 61.98% to $46.1 million in 2024, then soared by 105.64% to $70.7 million in 2025.
  • Its Invested Capital stands at $70.7 million for Q3 2025, versus $64.2 million for Q2 2025 and $55.3 million for Q1 2025.